Research location

Buffalo

New York, United States

Published trials1,288

Site observations1,345

Linked trials published1,288

Page2 / 26

Research activity in Buffalo

New York, United States

CureCurrent currently publishes aggregate city-level research activity for this location: 1,288 trials and 1,345 site observations.

The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.

Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.

Trials with sites in Buffalo

1,288 linked trials · page 2 of 26

A Post-treatment Supportive Service Program for the Transition Into Survivorship for Black Women Breast Cancer Survivors in Western New YorkNCT06833255 · 2025-04-21 · 1 site observation

A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung CancerNCT06868277 · 2025-04-10 · 1 site observation

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT TrialNCT06498635 · 2025-04-01 · 1 site observation

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)NCT06883305 · 2025-03-18 · 2 site observations

A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood PressureNCT06742723 · 2025-03-03 · 1 site observation

A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)NCT06780137 · 2025-02-27 · 1 site observation

A Phase I Study of SIM0505 in Participants With Advanced Solid TumorsNCT06792552 · 2025-02-26 · 1 site observation

Vaping and Smoking Project in People With SchizophreniaNCT06944847 · 2025-02-15 · 1 site observation

Targeted Treatment for Metastatic Prostate Cancer, The PREDICT TrialNCT06632977 · 2025-02-06 · 1 site observation

REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRENCT06777368 · 2025-02-06 · 1 site observation

Testosterone Replacement Therapy for the Treatment of Low Testosterone in Hypogonadal Men With Localized Prostate Cancer on Active SurveillanceNCT06733350 · 2025-01-15 · 1 site observation

A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)NCT06739122 · 2025-01-10 · 1 site observation

A Phase 1 Study of LNCB74 in Advanced Solid TumorsNCT06774963 · 2025-01-07 · 1 site observation

A Patient Navigation Program for Addressing Disparities in Breast Cancer CareNCT06350500 · 2024-12-15 · 1 site observation

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLCNCT06627647 · 2024-11-27 · 1 site observation

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)NCT06692738 · 2024-11-18 · 1 site observation

A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)NCT06672549 · 2024-11-18 · 1 site observation

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)NCT06623422 · 2024-10-21 · 1 site observation

Registry for Stage 2 Type 1 DiabetesNCT06481904 · 2024-09-27 · 1 site observation

Project ASTHMA - Aligning With Schools To Help Manage Asthma and Improve OutcomesNCT06539312 · 2024-09-27 · 1 site observation

Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET TrialNCT06563388 · 2024-09-18 · 1 site observation

Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast CancerNCT05741164 · 2024-09-01 · 1 site observation

Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia SymptomsNCT06559306 · 2024-07-25 · 1 site observation

Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.NCT06590857 · 2024-07-19 · 1 site observation

Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast CancersNCT05846789 · 2024-07-02 · 1 site observation

Global Paradise System US Post Approval StudyNCT06297291 · 2024-06-28 · 1 site observation

A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)NCT06439277 · 2024-06-03 · 1 site observation

Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung CancerNCT06343402 · 2024-05-22 · 1 site observation

A Phase 1 of CTX-8371 in Patients With Advanced MalignanciesNCT06150664 · 2024-03-19 · 1 site observation

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid TumorsNCT06172478 · 2024-02-26 · 1 site observation

A Study of ZL-1310 in Subjects With Small Cell Lung CancerNCT06179069 · 2024-01-23 · 1 site observation

Quality of Life Intervention to Inform Patient Decision-Making in Early-Stage Lung CancerNCT05292521 · 2023-12-21 · 1 site observation

Intermittent Fasting in Prostate Cancer Patients Receiving Androgen Deprivation TherapyNCT06172283 · 2023-12-05 · 1 site observation

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25NCT05879926 · 2023-10-18 · 1 site observation

Home-based Respiratory Muscle Training for Minimizing Side Effects in Patients Undergoing Treatment for CancerNCT05787834 · 2023-10-16 · 1 site observation

Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 DiabetesNCT06144554 · 2023-09-25 · 1 site observation

Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast TumorsNCT03463954 · 2023-08-09 · 1 site observation

Glaucoma Drainage Device and Endothelial Cell Loss Compare TrialNCT05924477 · 2023-07-11 · 1 site observation

Trial to Evaluate the Safety and Effectiveness of Treatment With COMS One Device in Subjects With Diabetic Foot UlcersNCT05758545 · 2023-06-19 · 1 site observation

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus PembrolizumabNCT05812807 · 2023-06-14 · 1 site observation

Trauma-informed Approach to Timely Detection and Management of Early Postpartum HypertensionNCT05884190 · 2023-06-12 · 1 site observation

Empathic Communication Skills (ECS) TrainingNCT05456841 · 2023-04-28 · 1 site observation

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialNCT05564377 · 2023-04-07 · 1 site observation

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced CancerNCT05735080 · 2023-03-28 · 1 site observation

Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast CancerNCT04348747 · 2022-12-19 · 1 site observation

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)NCT05633654 · 2022-12-12 · 1 site observation

Comparison of Intraocular Pressure Measurement With the Novel TonoVera Device With Other Commonly Used DevicesNCT05523622 · 2022-08-01 · 1 site observation

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung CancerNCT05061550 · 2022-04-14 · 1 site observation

Assessment of CCM in HF With Higher Ejection FractionNCT05064709 · 2022-02-03 · 1 site observation

A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate CancerNCT05125016 · 2021-11-30 · 1 site observation

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.